Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho IV infliximab Coverage Update | Op…
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy 5.01.502

    Intravenous infliximab (medical benefit)

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy 5.01.502 alerts

    Get alerted when Policy 5.01.502 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, dosing, continuation, and prior-authorization limits for intravenous infliximab under Blue Cross of Idaho medical benefit plans; affects providers requesting IV infliximab for covered indications.

    Policy Summary
    PayerBluecross Idaho
    PolicyIntravenous infliximab (medical benefit)
    Policy CodePolicy 5.01.502
    Change TypePreferred product updatepolicy adoption into prescription drug section
    Effective DateJan 1, 2026
    Last ReviewSep 25, 2025
    Next Review DateSep 25, 2025
    Key ActionObtain prior authorization and document TB screening within 6 months before initiating IV infliximab.
    SourceLink
    POLICY UPDATE CHANGES

    Remicade added as a preferred product.

    Policy added to prescription drug section and adopted by Blue Cross of Idaho.

    100 mg vialPrior-approval product/packaging
    up to 10 mg/kgMax dose listed
    16 weeksInitial approval for escalation
    6 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Continued approval for escalation
    MultipleAdult indications
    NotedBlack box warnings

    Coverage Criteria for Intravenous Infliximab

    Initial therapy criteria

    Initial Treatment — Intravenous infliximab may be considered medically necessary when ALL of the following are met:

    Product selection: Request is for one of the following preferred products for Blue Cross of Idaho commercial plan members: Inflectra (infliximab-dyyb); Unbranded infliximab (NDC: 57894-0160-01 only); or Remicade (infliximab)
    Prior product failure/contraindication: Individual has a documented contraindication, intolerance, or adverse response to all preferred products in the drug class or has used the preferred products with inadequate therapeutic response

    Documentation of prior therapies should be provided as specified in indication-specific sections

    TB screening: Individual has had tuberculosis (TB) screening within 6 months confirming no active tuberculosis; if latent TB is present, treatment for the infection must be started prior to use of infliximab; if switching from another targeted immune modulator with prior TB screening and there are no new risk factors, repeat TB screening is not necessary

    See pre-treatment screening requirements

    No concurrent biologics: Infliximab is NOT being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator

    See Appendices for lists of biologic and targeted synthetic DMARDs

    Dosing guidance: Dosing is initiated in accordance with FDA‑approved labeling and/or accepted drug compendia dosing (see Additional Dosing Information)

    See Dose Escalation section for permitted increases

    Indication-specific criteria: For each covered indication (e.g., PJIA, Crohn's disease, ulcerative colitis, RA, AS/axial spondyloarthritis, PsO, PsA, Behçet's, GPA, HS, pyoderma gangrenosum, sarcoidosis, Takayasu's arteritis, non-infectious uveitis, immune checkpoint inhibitor–related toxicities, acute GVHD) the specific age and prior therapy requirements listed in the policy must be met (for example, age limits and required inadequate response/intolerance to conventional therapies as specified)

    See chunks 6–10 for indication-specific lines of therapy and age criteria

    Continuation therapy criteria

    Continuation of Treatment — requests may be considered medically necessary when ALL of the following are met:

    Prior approval met: Coverage criteria for initiation of infliximab therapy for the requested indication has previously been met
    Clinical benefit: There is clinically significant and functionally relevant improvement or stabilization in clinical signs and symptoms of the disease
    No concurrent biologics: Infliximab is NOT being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator

    See Appendices

    Dose escalation criteria (RA, CD, UC)

    Dose escalation for IV infliximab — additional dosing may be authorized when ALL of the following are met (criteria differ by disease):

    RA escalation: For rheumatoid arthritis: dose escalation up to 10 mg/kg every 8 weeks OR 5 mg/kg every 4 weeks for individuals who have an incomplete response to initial dosing
    CD/UC adult escalation: For Crohn's disease or ulcerative colitis in adults: escalation up to 10 mg/kg every 8 weeks OR 5 mg/kg every 4 weeks if the individual is ≥18 years, has been treated with standard maintenance dosing (every 8 weeks) for at least 2 doses (16 weeks), initially achieved an adequate response then lost response or had an inadequate response, and symptoms are not due to active infection or another GI disorder

    Initial approval duration for increased dosing for CD/UC is 16 weeks; continued approval duration is 6 months

    CD/UC pediatric escalation: For pediatric individuals <18 years with severe Crohn's disease or severe ulcerative colitis: may approve up to 10 mg/kg every 4 weeks for initial or continuation of therapy; adults who initiated treatment when <18 may continue current dosage (up to 10 mg/kg every 4 weeks) if stable

    Indications (FDA-approved and Off-label)

    Policy references FDA-approved indications and lists commonly considered off-label uses

    FDA-approved indications: Infliximab is FDA-approved for pediatric patients 6 years and older for moderate to severely active Crohn's disease and ulcerative colitis; and for adults 18 years and older for Crohn's disease (including fistulizing disease), ulcerative colitis, rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis/axial spondyloarthritis, psoriatic arthritis, and chronic severe plaque psoriasis

    See regulatory status list in chunk 21 for full details

    Off-label/other uses: Off-label indications cited in the policy include axial spondylarthritis, Behçet's syndrome, granulomatosis with polyangiitis, hidradenitis suppurativa, polyarticular juvenile idiopathic arthritis, pyoderma gangrenosum, sarcoidosis, Takayasu's arteritis, non-infectious uveitis, immune checkpoint inhibitor–related toxicities, and acute graft‑versus‑host disease

    See chunk 22 for off-label list and safety warnings

    General coverage context and indication list

    Coverage and use of infliximab and biosimilars are context-dependent and typically considered after conventional therapies or as indicated by disease-specific guidance.

    Indications context: Infliximab and biosimilars are referenced for multiple immune‑mediated conditions including Crohn's disease, ulcerative colitis, rheumatologic diseases, dermatologic conditions, sarcoidosis, and graft‑versus‑host disease; treatment decisions should reference conventional therapy options (e.g., corticosteroids, azathioprine, methotrexate, mesalamine, antibiotics) and the lists of biologic and targeted synthetic DMARDs in the appendices

    See Appendices 1 and 2 for conventional therapy options and the list of biologic/targeted therapies

    Subcutaneous formulations of infliximab are managed under the pharmacy benefit and are outside the scope of this medical policy. Intravenous infliximab is covered under the Blue Cross of Idaho medical benefit when the medical necessity criteria in this policy are met. Infliximab must not be used concomitantly with other biologic disease-modifying antirheumatic drugs (DMARDs), targeted synthetic DMARDs, or other immunomodulators; see the policy appendices for details on concurrent therapy exclusions and preferred product guidance.

    Infliximab should not be administered to individuals with any clinically important active infection, including active tuberculosis, until the infection is adequately treated and resolved. Individuals should be screened for hepatitis B virus (HBV) prior to initiation because HBV reactivation has been reported with TNFα blocker therapy. Live vaccines are not recommended concurrently with infliximab; for infants exposed in utero, live vaccines should be delayed for at least 6 months after birth. Use in individuals with moderate to severe heart failure is cautioned and should follow consideration of alternative treatments.

    The codes listed in this policy are provided for reference only. Inclusion of a code does not guarantee member coverage or provider reimbursement. All coverage and reimbursement decisions are subject to the member’s specific benefit plan documentation, the terms of this medical policy, and applicable legal and contractual requirements; providers should verify member benefits and prior authorization requirements before billing.

    For Crohn’s disease and ulcerative colitis, requests for increased infliximab dosing will not be approved when the individual had no response to standard maintenance dosing (every 8 weeks). Dose escalation should only be considered for those who initially achieved an adequate response and subsequently lost response, and must not be requested based solely on therapeutic drug level or anti-drug antibody testing in the absence of clinical signs or symptoms. Adults’ escalation is limited to a maximum of 10 mg/kg every 8 weeks or 5 mg/kg every 4 weeks; pediatric patients with severe disease may be approved for up to 10 mg/kg every 4 weeks. Initial approval duration for increased dosing is 16 weeks with continued approval up to 6 months as specified in the policy.

    This medical policy may not apply to all lines of business. Benefit exceptions can include, but are not limited to, the Federal Employee Program, Medicare Supplement, Medicare Advantage, Medicaid, and certain self-insured groups. Providers should consult member-specific benefit plan documentation to confirm applicability, coverage rules, and any alternate processes that may apply for those lines of business.

    The policy text excerpt does not enumerate additional blanket ‘not medically necessary’ statements beyond the criteria already described; however, requests may be considered not medically necessary when the coverage criteria are not met (for example, active or untreated latent tuberculosis, hepatitis B, other active serious infections, or failure to meet prior‑therapy requirements). Final coverage determinations are made based on the member’s specific benefit plan documentation and the clinical criteria set forth in this policy.

    Coding and Dosing

    HCPCS/Drug CodesHCPCS
    J1745Injection, infliximab, excludes biosimilar, 10 mg (Remicade)
    J1748Injection, infliximab-hyphendyyb (zymfentra), 10 mg
    Q5103Injection, infliximab-hyphendyyb, biosimilar, (inflectra), 10 mg
    Q5104Injection, infliximab-hyphenabda, biosimilar, (renflexis), 10 mg
    Q5121Injection, infliximab-hyphenaxxq, biosimilar, (AVSOLA), 10 mg
    ICD-10 Diagnosis CodesICD-10
    D86.0 - D86.9Sarcoidosis
    D89.810Acute graft-versus-host disease
    D89.812Acute on chronic graft-versus-host disease
    K52.82Eosinophilic colitis
    K52.89Other specified noninfective gastroenteritis and colitis
    K52.9Noninfective gastroenteritis and colitis, unspecified
    K60.3 - K60.5Anal fistula
    K63.2Fistula of intestine, excluding rectum and anus
    L40.0 - L40.9Psoriasis
    L73.2Hidradenitis suppurativa
    1–10 of 19
    1/2
    Maximum infliximab dosing allowed
    Maximum adult dosing (permitted escalation)Up to 10 mg/kg every 8 weeks OR 5 mg/kg every 4 weeks (adults)
    Standard adult maintenance cadenceUsual maintenance dosing is 5 mg/kg every 8 weeks; escalation requires prior criteria be met
    Pediatric severe CD/UC dosingFor pediatric individuals <18 with severe Crohn's disease or severe ulcerative colitis, may approve up to 10 mg/kg every 4 weeks
    Adults who initiated as pediatricsAdults who initiated treatment at <18 may continue current dosage (up to 10 mg/kg every 4 weeks) if stable
    Approval durations for escalated dosingInitial approval for increased dosing (CD/UC) = 16 weeks; continued approval duration = 6 months

    Provider Requirements and Authorization Steps

    Prior Authorization

    Prior-approval limits: vial size, usual dosing, and non-preferred product rules

    Prior authorization requests are subject to prior-approval limits: dosing is referenced to a 100 mg vial with typical initiation at 5 mg/kg as frequently as every 8 weeks for up to 1 year; requests for non-preferred products must meet medical policy exceptions and preferred-product requirements in the policy.

    • Prior-approval limits: 100 mg vial; 5 mg/kg as frequently as every 8 weeks, for up to 1 year (See Additional Dosing Information).
    • Non-preferred product requests must meet coverage per medical policy and preferred-product listing.
    Prior Authorization

    Prior authorization required before initiation

    Prior authorization is required for infliximab to ensure safe, clinically appropriate, and cost-effective use and must be obtained before treatment per the medical policy.

    • Prior authorization is required to maintain optimal therapeutic outcomes.

    Background on Infliximab

    Infliximab is an intravenous tumor necrosis factor alpha (TNFα) inhibitor indicated for multiple immune-mediated inflammatory conditions, including rheumatoid arthritis (in combination with methotrexate), Crohn’s disease (including fistulizing disease), ulcerative colitis, ankylosing spondylitis/axial spondyloarthritis, psoriatic arthritis, and chronic severe plaque psoriasis; pediatric approvals include certain indications for Crohn’s disease and ulcerative colitis for patients aged 6 years and older. The policy requires tuberculosis screening prior to initiation and prohibits concurrent use with other biologic or targeted synthetic DMARDs. Safety concerns noted with TNFα blockers include serious infections, potential hepatitis B reactivation, and rare malignancies; vaccination and HBV screening recommendations should be followed per the policy.

    Definitions and Safety Notes

    TB screening
    Timing of TB testTuberculosis screening test performed within 6 months of initiating therapy confirming no active tuberculosis
    Latent TB managementIf latent tuberculosis infection is present, treatment for the infection must be started prior to use of infliximab
    When repeat screening not neededIf switching from another targeted immune modulator that required TB screening at initiation and there are no new risk factors, repeat TB screening is not necessary
    Infliximab mechanism
    Mechanism of actionBinds and neutralizes tumor necrosis factor alpha (TNFα), a proinflammatory cytokine
    Clinical effectDecreases inflammatory response, reduces symptoms, and helps prevent further tissue damage in autoimmune diseases

    Policy Revision History

    2026-01-01effective_dateLatest

    Policy adopted by Blue Cross of Idaho with Remicade added as a preferred product; policy effective date recorded.

    2025-09-25review

    Policy last reviewed; New policy added to prescription drug section and Blue Cross of Idaho adoption documented; adoption effective 08/01/2025 noted in history.

    2025-04-26creation
    Policy Summary
    PayerBluecross Idaho
    PolicyIntravenous infliximab (medical benefit)
    Policy CodePolicy 5.01.502
    Change TypePreferred product updatepolicy adoption into prescription drug section
    Effective DateJan 1, 2026
    Last ReviewSep 25, 2025
    Next Review DateSep 25, 2025
    Key ActionObtain prior authorization and document TB screening within 6 months before initiating IV infliximab.
    SourceLink
    On This Page
    Coverage Criteria for Intravenous InfliximabCoding and DosingProvider Requirements and Authorization StepsBackground on InfliximabDefinitions and Safety NotesPolicy Revision History
    Escalation limits and reassessment: Requested dosing must not exceed 10 mg/kg every 8 weeks (or 5 mg/kg every 4 weeks) for adults or 10 mg/kg every 4 weeks for pediatrics; increased dosing will not be approved for primary nonresponders (no response to standard maintenance dosing) or when escalation is requested solely based on therapeutic drug level or anti-drug antibody testing without clinical signs/symptoms; individuals on increased dosing must be reassessed and considered for de-escalation

    Initial approval for increased dosing (CD/UC) = 16 weeks; continued approval = 6 months

    Conventional therapy prerequisites
    CorticosteroidsPrednisone, methylprednisolone, hydrocortisone used for induction/acute management as appropriate per disease
    Immunomodulators (thiopurines)Azathioprine, mercaptopurine used for maintenance in Crohn's disease and ulcerative colitis
    MethotrexateMethotrexate (including IM) listed as alternative induction/maintenance option in CD and UC contexts
    5-ASA agents / mesalamineOral and rectal mesalamine (e.g., Asacol, Lialda, Pentasa, Canasa, Rowasa) for mild–moderate UC induction and maintenance
    Antibiotics for fistulizing diseaseMetronidazole ± ciprofloxacin for perianal and fistulizing Crohn's disease induction and maintenance
    Billing Rule

    Prior authorization applies to infliximab (J- and Q-codes) and biosimilars

    Prior authorization applies to infliximab and its biosimilars (HCPCS/HCPCS Q-codes and J-codes listed in the policy); providers must follow member-specific prior authorization processes and billing guidance.

    • Relevant codes cited in the policy include J1745, J1748, Q5103, Q5104, and Q5121.
    • Inclusion of codes in the policy does not guarantee coverage or reimbursement; verify member benefits.
    Step Therapy

    Step therapy — document prior-line failure/intolerance/contraindication

    Providers must document inadequate response, intolerance, or contraindication to preferred infliximab products or to conventional (nonbiologic) therapies as specified for each indication before IV infliximab will be authorized.

    • Initial therapy requires use of a preferred product or documentation of contraindication/intolerance or inadequate response to preferred products.
    • Indication-specific criteria list required prior conventional therapy failures (see indication sections and Appendices).
    Step Therapy

    Document prior inadequate response to conventional therapy for FDA‑approved indications

    For many FDA-approved indications (e.g., pediatric CD/UC, adult CD/UC), infliximab use is contingent on documentation of prior inadequate response to conventional therapy; expect documentation of those prior therapies when requesting coverage.

    • Pediatrics ≥6 years: moderate-to-severe CD or UC with inadequate response to conventional therapy.
    • Adults: CD/UC use after inadequate response to conventional therapy is an FDA-approved indication and referenced in the policy.
    Note

    Document conventional therapy alternatives and prior use

    Providers should document use of conventional therapy alternatives (as appropriate per disease) prior to biologic initiation or to support step therapy exceptions; listed options include corticosteroids, azathioprine, methotrexate, antibiotics for fistulizing disease, and mesalamine for UC.

    • Crohn's disease conventional options: mesalamine/budesonide for mild disease, azathioprine/mercaptopurine or methotrexate for maintenance; antibiotics for perianal/fistulizing disease.
    • Ulcerative colitis conventional options: oral/rectal mesalamine, corticosteroids for induction, azathioprine/mercaptopurine for maintenance, and other listed alternatives per severity.
    Documentation Required

    Documentation required: TB screening and prior-therapy evidence

    Documentation must include tuberculosis screening within 6 months prior to initiating infliximab confirming no active TB, or documentation that latent TB treatment was started prior to infliximab; clinical rationale for intolerance/contraindication or inadequate response to prior therapies must also be provided.

    • TB screening within 6 months confirming no active tuberculosis, or evidence latent TB treatment was begun before infliximab.
    • If switching from another targeted immune modulator with prior TB screening and no new risk factors, repeat TB screening is not necessary.
    • Documentation of prior therapy failure, intolerance, or contraindication as specified per indication.
    Documentation Required

    Pre-treatment screening: HBV and immunizations

    Screen for hepatitis B virus (HBV) prior to starting infliximab and ensure members are up-to-date on immunizations; live vaccines are not recommended concurrently with infliximab and infants exposed in utero should not receive live vaccines for at least 6 months.

    • Individuals should be screened for HBV prior to initiation due to risk of HBV reactivation.
    • Ensure vaccination status per current guidelines; do not give live vaccines concurrently with infliximab.
    Billing Rule

    Verify member benefits and cite policy when billing

    When submitting claims, providers must verify member-specific benefit plan coverage and reference this medical policy; the policy's code list is for reference and does not guarantee coverage or payment.

    • Reference member-specific benefits and this medical policy when submitting claims.
    • The inclusion of a code in the policy does not guarantee coverage or reimbursement.
    Denial Risk

    Denial risks: active infections, HBV, untreated latent TB, and non-preferred products

    Requests may be denied as not medically necessary for individuals with active or untreated latent tuberculosis, hepatitis B, other active serious infections, a history of recurrent infections, or when criteria (including preferred-product requirements) are not met.

    • Active or untreated latent TB, active HBV, or other active serious infections are contraindications to approval.
    • Requests for non-preferred medications will be considered not medically necessary unless policy exceptions are met.
    Denial Risk

    Risk of denial if prior authorization is not obtained

    Failure to obtain required prior authorization may result in non-coverage or denial of infliximab claims; obtain authorization per member-specific process before administration.

    • Prior authorization is explicitly required by the policy to ensure appropriate use.
    • Obtain authorization before treatment to avoid potential non-coverage.
    Note

    Coverage is contingent on member-specific benefits and plan terms

    Coverage determination for an individual is contingent on that member's specific benefit plan; inclusion of HCPCS or ICD-10 codes in this policy does not guarantee coverage under a given plan.

    • All benefit coverage determinations are subject to member-specific benefit plan documentation and other terms and conditions.
    • Verify plan-level coverage even when policy criteria are met.
    Therapeutic roleUsed as an anti‑TNF biologic for conditions with elevated TNFα such as RA, IBD, psoriasis, and spondyloarthropathies
    Serious infections and malignancies (black box warnings)
    Black box warnings (infections & malignancy)Infliximab has boxed warnings for increased risk of serious infections and malignancies; should not be given to individuals with active infection or active TB
    HBV reactivation riskAssociated with reactivation of hepatitis B virus in chronic carriers; screen for HBV prior to initiation
    Hepatosplenic T‑cell lymphoma reportsPost‑marketing cases of aggressive and fatal hepatosplenic T‑cell lymphoma reported with TNFα blockers, including infliximab
    Hematologic abnormalitiesReported leukopenia, neutropenia, thrombocytopenia, and pancytopenia; monitor and consider discontinuation if significant abnormalities develop
    Biologic DMARDs
    Examples of biologic DMARDs abatacept (Orencia), adalimumab (Humira), infliximab (Remicade/Avsola/Inflectra/Renflexis), rituximab (Rituxan/Riabni/etc.), tocilizumab (Actemra), ustekinumab (Stelara), vedolizumab (Entyvio)
    Class roleBiologic DMARDs are listed as alternative or concomitant therapy classes; policy prohibits concurrent use of infliximab with other biologic DMARDs
    Examples continuedOther listed agents include certolizumab, etanercept, golimumab, ixekizumab, risankizumab, sarilumab, secukinumab
    Targeted synthetic DMARDs
    Examples of targeted synthetic DMARDsApremilast (Otezla), baricitinib (Olumiant), deucravacitinib (Sotyktu), tofacitinib (Xeljanz/XR), upadacitinib (Rinvoq)
    Administration routeThese are oral small‑molecule agents used for immune‑mediated conditions
    Policy interactionInfliximab should not be used in combination with targeted synthetic DMARDs per policy

    Policy created and replaced prior policy content; initial drafting/replace action recorded in policy history.